Incyte Corp Analyst and Investor Event Transcript

Dec 12, 2022 / 02:00AM GMT
Steven H. Stein - Incyte Corporation - Executive VP & Chief Medical Officer

All right. Good evening, everybody. Thank you for joining us. We'll start the meeting. It's really good to be here at the American Society of Hematology in person, in New Orleans, and this meeting is also joined by people on Webex as well. So thank you for being here.

I just want to tell everybody from the beginning that safe harbor rules govern my remarks, those of my colleagues on the stage with me tonight and as well as any forward-looking statements, and I'd tell you to consult our SEC documents and for risks associated with anything we speak about.

In terms of tonight's agenda, I am Steven Stein. I'm the Incyte Chief Medical Officer and Head of Development, and I'll be taking you through the agenda tonight and then at the end, wrapping up and -- as well as the Q&A, for which we should have about 15 to 20 minutes if everything goes according to plan.

The presence we have at ASH is a really big deal for Incyte this year, both quantitatively and qualitatively. We had 57 abstracts accepted, 16

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot